A Phase II Evaluation of Afatanib, an Irreversible Human Epidermal Growth Factor Receptor 2 (Her2/Neu) Tyrosine Kinase Inhibitor, in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
Latest Information Update: 19 Jul 2023
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Uterine cancer
- Focus Therapeutic Use
- 15 May 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jul 2024.
- 14 Jan 2021 Status changed from active, no longer recruiting to recruiting.
- 10 Apr 2020 Planned End Date changed from 1 Jun 2028 to 1 Jul 2028.